IGC (IGC Pharma Inc.) stock: $0.20, $23.1M market cap, $0.4M cash, $22.8M EV, $20.7M fully diluted market cap. Lead program: IGC-AD1-Active (Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
Our mission is to improve the lives of individuals affected by Alzheimer’s disease by addressing both its symptoms and the disease. Our near-term focus is on advancing IGC-AD1, our lead drug candidate currently in Phase 2 clinical trials targeting agitation in Alzheimer’s patients.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead candidate in CALMA, a randomized double-blind placebo-controlled Phase 2 trial; 146-patient enrollment target reached June 2026, over-enrollment and follow-up ongoing; database lock, site closeout and topline analysis expected next (no date stated). Phase 1 safety completed. Preclinical data suggest activity against AD pathology pathways.
TGR-63
Preclinical · Active
Target amyloid-beta (Aβ)
Indications
Alzheimer's disease(Preclinical)
Status note Earlier-stage candidate targeting AD mechanisms, in preclinical evaluation; no target, modality or indication detail stated.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline
Lead drug
IGC-AD1-Active
Lead indication
Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden
Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.